Interestingly, ex vivo analysis of tumor progression in one recipient following NKp30-CD28 TCRKO CAR T-treatment revealed no measurable B7H6 cell surface expression in the isolated cells from the tumor specimen (Figure S2). This evidence concerns the gene CD28 and neoplasm.